Vitamin D receptor agonists as anti-inflammatory agents

References

• Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. Faseb J.15, 2579–2585 (2001).
   PubMed Web of Science ®Google Scholar
• Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol. Med.8, 174–179. (2002).
   PubMed Web of Science ®Google Scholar
• Griffin MD, Xing N, Kumar R. Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu. Rev. Nutr.23, 117–145 (2003).
   PubMed Web of Science ®Google Scholar
• Carlberg C. Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Recent Results Cancer Res.164, 29–42 (2003).
   PubMedGoogle Scholar
• Adorini L. Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell. Immunol.233, 115–124 (2005).
   PubMed Web of Science ®Google Scholar
• Griffin MD, Kumar R. Multiple potential clinical benefits for 1α,25-dihydroxyvitamin D3 analogs in kidney transplant recipients. J. Steroid Biochem. Mol. Biol.97, 213–218 (2005).
   PubMedGoogle Scholar
• Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch. Biochem. Biophys.374, 334–338 (2000).
   PubMed Web of Science ®Google Scholar
• Adorini L, Giarratana N, Penna G. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin. Immunol.16, 127–134 (2004).
   PubMed Web of Science ®Google Scholar
• Liu PT, Stenger S, Li H et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science311, 1770–1773 (2006).
   PubMed Web of Science ®Google Scholar
• Wang TT, Nestel FP, Bourdeau V et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol.173, 2909–2912 (2004).
   PubMed Web of Science ®Google Scholar
• Cadranel J, Garabedian M, Milleron B, Guillozo H, Akoun G, Hance AJ. 1,25(OH)2D3 production by T lymphocytes and alveolar macrophages recovered by lavage from normocalcemic patients with tuberculosis. J. Clin. Invest.85, 1588–1593 (1990).
   PubMed Web of Science ®Google Scholar
• Schauber J, Dorschner RA, Coda AB et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J. Clin. Invest.117, 803–811 (2007).
   PubMed Web of Science ®Google Scholar
• Sigmundsdottir H, Pan J, Debes GF et al. DCs metabolize sunlight-induced vitamin D3 to ‘program’ T cell attraction to the epidermal chemokine CCL27. Nat. Immunol.8, 285–293 (2007).
   PubMed Web of Science ®Google Scholar
• Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol.311, 17–18 (2006).
   PubMed Web of Science ®Google Scholar
• Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol.23, 275–306 (2005).
   PubMed Web of Science ®Google Scholar
• Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat. Rev. Immunol.4, 24–34 (2004).
   PubMed Web of Science ®Google Scholar
• Adorini L, Penna G, Giarratana N et al. Dendritic cells as key targets for immunomodulation by vitamin D receptor ligands. J. Steroid Biochem. Mol. Biol. 89–90, 437–441 (2004).
   PubMed Web of Science ®Google Scholar
• Penna G, Roncari A, Amuchastegui S et al. Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. Blood106, 3490–3497 (2005).
   PubMed Web of Science ®Google Scholar
• Martin E, O’Sullivan B, Low P, Thomas R. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity18, 155–167 (2003).
   PubMed Web of Science ®Google Scholar
• Rachez C, Freedman LP. Mechanisms of gene regulation by vitamin D(3) receptor: a network of coactivator interactions. Gene246, 9–21 (2000).
   PubMed Web of Science ®Google Scholar
• Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L. Regulatory T cells induced by 1α,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol.167, 1945–1953 (2001).
   PubMed Web of Science ®Google Scholar
• Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R. Dendritic cell modulation by 1α,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl Acad. Sci. USA22, 22 (2001).
   Google Scholar
• Adorini L, Penna G, Giarratana N, Uskokovic M. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J. Cell. Biochem.88, 227–233 (2003).
   PubMed Web of Science ®Google Scholar
• Penna G, Amuchastegui S, Giarratana N et al. 1,25-dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J. Immunol.178, 145–153 (2007).
   PubMed Web of Science ®Google Scholar
• Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr. Rev.26, 662–687 (2005).
   PubMed Web of Science ®Google Scholar
• Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O’Garra A. 1α,25-dihydroxyvitamin D3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J. Immunol.167, 4974–4980. (2001).
   PubMed Web of Science ®Google Scholar
• Mahon BD, Wittke A, Weaver V, Cantorna MT. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J. Cell. Biochem.89, 922–932 (2003).
   PubMed Web of Science ®Google Scholar
• Adorini L. Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases. Int. Immunopharmacol.2, 1017–1028. (2002).
   PubMed Web of Science ®Google Scholar
• Penna G, Amuchastegui S, Cossetti C et al. Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J. Immunol.177, 8504–8511 (2006).
   PubMed Web of Science ®Google Scholar
• Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med.13, 139–145 (2007).
   PubMed Web of Science ®Google Scholar
• De Bosscher K, Vanden Berghe W, Haegeman G. Cross-talk between nuclear receptors and nuclear factor κB. Oncogene25, 6868–6886 (2006).
   PubMed Web of Science ®Google Scholar
• Li Q, Verma IM. NF-κB regulation in the immune system. Nat. Rev. Immunol.2, 725–734 (2002).
   PubMed Web of Science ®Google Scholar
• Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev.18, 2195–2224 (2004).
   PubMed Web of Science ®Google Scholar
• Dong X, Craig T, Xing N et al. Direct transcriptional regulation of RelB by 1α,25-dihydroxyvitamin D3 and its analogs: physiologic and therapeutic implications for dendritic cell function. J. Biol. Chem.278, 49378–49385 (2003).
   PubMed Web of Science ®Google Scholar
• Giarratana N, Penna G, Amuchastegui S, Mariani R, Daniel KC, Adorini L. A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and Type 1 diabetes development. J. Immunol.173, 2280–2287 (2004).
   PubMed Web of Science ®Google Scholar
• Cohen-Lahav M, Shany S, Tobvin D, Chaimovitz C, Douvdevani A. Vitamin D decreases NFκB activity by increasing IκBα levels. Nephrol. Dial. Transplant.21, 889–897 (2006).
   PubMed Web of Science ®Google Scholar
• Nonn L, Peng L, Feldman D, Peehl DM. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res.66, 4516–4524 (2006).
   PubMed Web of Science ®Google Scholar
• Sun J, Kong J, Duan Y et al. Increased NF-κB activity in fibroblasts lacking the vitamin D receptor. Am. J. Physiol. Endocrinol. Metab.291, E315–E322 (2006).
   Google Scholar
• Hewison M, Freeman L, Hughes SV et al. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J. Immunol.170, 5382–5390 (2003).
   PubMed Web of Science ®Google Scholar
• Dong X, Lutz W, Schroeder TM et al. Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter. Proc. Natl Acad. Sci. USA102, 16007–16012 (2005).
   PubMed Web of Science ®Google Scholar
• Penna G, Adorini L. 1α,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol.164, 2405–2411 (2000).
   PubMed Web of Science ®Google Scholar
• Xing N, ML LM, Bachman LA, McKean DJ, Kumar R, Griffin MD. Distinctive dendritic cell modulation by vitamin D(3) and glucocorticoid pathways. Biochem. Biophys. Res. Commun.297, 645–652 (2002).
   PubMedGoogle Scholar
• Cohen-Lahav M, Douvdevani A, Chaimovitz C, Shany S. The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages. J. Steroid Biochem. Mol. Biol.103(3–5), 558–562 (2006).
   PubMedGoogle Scholar
• Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes from Type 2 diabetic patients have a pro-inflammatory profile 1,25-dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res. Clin. Pract. (2006).
   PubMedGoogle Scholar
• Gregori G, Giarratana N, Smiroldo S, Uskokovic M, Adorini L. A 1α,25-dihydroxyvitamin D3 analog enhances regulatory T cells and arrests autoimmune diabetes in NOD mice. Diabetes51, 1367–1374 (2002).
   PubMed Web of Science ®Google Scholar
• D’Ambrosio D, Sinigaglia F, Adorini L. Special attractions for suppressor T cells. Trends Immunol.24, 122–126 (2003).
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med.10, 942–949 (2004).
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T-cells in B-cell non-Hodgkin lymphoma. Blood (2006).
   Google Scholar
• Barrat FJ, Cua DJ, Boonstra A et al.In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med.195, 603–616 (2002).
   PubMed Web of Science ®Google Scholar
• Grant WB. Epidemiology of disease risks in relation to vitamin D insufficiency. Prog. Biophys. Mol. Biol.92, 65–79 (2006).
   PubMed Web of Science ®Google Scholar
• Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin. Proc.81, 353–373 (2006).
   PubMed Web of Science ®Google Scholar
• van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J. Steroid Biochem. Mol. Biol.97, 93–101 (2005).
   PubMed Web of Science ®Google Scholar
• Cantorna MT. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog. Biophys. Mol. Biol.92, 60–64 (2006).
   PubMed Web of Science ®Google Scholar
• Adorini L, Gregori S, Harrison LC. Understanding autoimmune diabetes: insights from mouse models. Trends Mol. Med.8, 31–38. (2002).
   PubMed Web of Science ®Google Scholar
• Adorini L, Penna G, Giarratana N, Mariani R, Uskokovic M. Inhibition of Type 1 diabetes development by vitamin D receptor agonists. Curr. Med. Chem.4, 645–651 (2005).
   Google Scholar
• Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA296, 2832–2838 (2006).
   PubMed Web of Science ®Google Scholar
• Brown SJ. The role of vitamin D in multiple sclerosis. Ann. Pharmacother.40, 1158–1161 (2006).
   PubMed Web of Science ®Google Scholar
• Muthian G, Raikwar HP, Rajasingh J, Bright JJ. 1,25 dihydroxyvitamin-D3 modulates JAK-STAT pathway in IL-12/IFNγ axis leading to Th1 response in experimental allergic encephalomyelitis. J. Neurosci. Res.83, 1299–1309 (2006).
   PubMed Web of Science ®Google Scholar
• Spach KM, Nashold FE, Dittel BN, Hayes CE. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J. Immunol.177, 6030–6037 (2006).
   PubMed Web of Science ®Google Scholar
• Dresner-Pollak R, Ackerman Z, Eliakim R, Karban A, Chowers Y, Fidder HH. The BsmI vitamin D receptor gene polymorphism is associated with ulcerative colitis in Jewish Ashkenazi patients. Genet. Test.8, 417–420 (2004).
   PubMedGoogle Scholar
• Pappa HM, Grand RJ, Gordon CM. Report on the vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. Inflamm. Bowel Dis.12, 1162–1174 (2006).
   PubMed Web of Science ®Google Scholar
• Neurath MF. IL-23: a master regulator in Crohn disease. Nat. Med.13, 26–28 (2007).
   PubMed Web of Science ®Google Scholar
• Froicu M, Zhu Y, Cantorna MT. Vitamin D receptor is required to control gastrointestinal immunity in IL-10 knockout mice. Immunology117, 310–318 (2006).
   PubMed Web of Science ®Google Scholar
• Froicu M, Cantorna MT. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol.8, 5 (2007).
   PubMed Web of Science ®Google Scholar
• Zhu Y, Mahon BD, Froicu M, Cantorna MT. Calcium and 1 α,25-dihydroxyvitamin D3 target the TNF-α pathway to suppress experimental inflammatory bowel disease. Eur. J. Immunol.35, 217–224 (2005).
   PubMed Web of Science ®Google Scholar
• Daniel C, Radeke HH, Sartory NA et al. The new low calcemic vitamin D analog 22-ene-25-oxa-vitamin D prominently ameliorates T helper cell type 1-mediated colitis in mice. J. Pharmacol. Exp. Ther.319, 622–631 (2006).
   PubMed Web of Science ®Google Scholar
• Stio M, Martinesi M, Bruni S et al. The Vitamin D analogue TX 527 blocks NF-κB activation in peripheral blood mononuclear cells of patients with Crohn’s disease. J. Steroid Biochem. Mol. Biol.103, 51–60 (2007).
   PubMedGoogle Scholar
• Krieger JN, Riley DE, Cheah PY, Liong ML, Yuen KH. Epidemiology of prostatitis: new evidence for a world-wide problem. World J. Urol.21, 70–74 (2003).
   PubMed Web of Science ®Google Scholar
• Pontari MA, Ruggieri MR. Mechanisms in prostatitis/chronic pelvic pain syndrome. J. Urol.172, 839–845 (2004).
   PubMed Web of Science ®Google Scholar
• Crescioli C, Ferruzzi P, Caporali A et al. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur. J. Endocrinol.150, 591–603 (2004).
   PubMed Web of Science ®Google Scholar
• Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr. Opin. Urol.16, 25–29 (2006).
   PubMed Web of Science ®Google Scholar
• Tinker AC, Wallace AV. Selective inhibitors of inducible nitric oxide synthase: potential agents for the treatment of inflammatory diseases? Curr. Top. Med. Chem.6, 77–92 (2006).
   PubMed Web of Science ®Google Scholar
• Krishnan AV, Moreno J, Nonn L et al. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J. Steroid Biochem. Mol. Biol. (2007).
   PubMedGoogle Scholar
• Colli E, Rigatti P, Montorsi F et al. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur. Urol.49, 82–86 (2006).
   PubMed Web of Science ®Google Scholar
• Adorini L. 1,25-dihydroxyvitamin D3 analogs as potential therapies in transplantation. Curr. Opin. Investig. Drugs.3, 1458–1463 (2002).
   PubMedGoogle Scholar
• Becker BN, Hullett DA, O’Herrin JK, Malin G, Sollinger HW, DeLuca H. Vitamin D as immunomodulatory therapy for kidney transplantation. Transplantation74, 1204–1206 (2002).
   PubMed Web of Science ®Google Scholar
• Mathieu C, Jafari M. Immunomodulation by 1,25-dihydroxyvitamin D3: therapeutic implications in hemodialysis and renal transplantation. Clin. Nephrol.66, 275–283 (2006).
   PubMedGoogle Scholar
• van Etten E, Branisteanu DD, Verstuyf A, Waer M, Bouillon R, Mathieu C. Analogs of 1,25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosuppressants. Transplantation69, 1932–1942. (2000).
   PubMedGoogle Scholar
• Gysemans C, Waer M, Laureys J, Bouillon R, Mathieu C. A combination of KH1060, a vitamin D(3) analogue, and cyclosporin prevents early graft failure and prolongs graft survival of xenogeneic islets in nonobese diabetic mice. Transplant. Proc.33, 2365. (2001).
   PubMedGoogle Scholar
• Raisanen-Sokolowski AK, Pakkala IS, Samila SP, Binderup L, Hayry PJ, Pakkala ST. A vitamin D analog, MC1288, inhibits adventitial inflammation and suppresses intimal lesions in rat aortic allografts. Transplantation63, 936–941 (1997).
   PubMed Web of Science ®Google Scholar
• Stammberger U, Kubisa B, Gugger M et al. Strong additive effect of 1,25-dihydroxycholecalciferol and cyclosporine A but not tacrolimus in rat lung allotransplantation. Eur. J. Cardiothorac. Surg.24, 196–200; discussion 200 (2003).
   PubMedGoogle Scholar
• Vierboom M, Johnsson C, t Hart B, Jonker M. Monotherapy with the vitamin D analogue MC1288 does not result in prolonged kidney allograft survival in rhesus monkeys. Transpl. Int.19, 396–403 (2006).
   PubMedGoogle Scholar
• Amuchastegui S, Daniel KC, Adorini L. Inhibition of acute and chronic allograft rejection in mouse models by BXL-628, a nonhypercalcemic vitamin D receptor agonist. Transplantation80, 81–87 (2005).
   PubMed Web of Science ®Google Scholar
• Adorini L, Amuchastegui S, Daniel KC. Prevention of chronic allograft rejection by Vitamin D receptor agonists. Immunol. Lett.100, 34–41 (2005).
   PubMed Web of Science ®Google Scholar
• Campbell MJ, Adorini L. The vitamin D receptor as a therapeutic target. Expert Opin. Ther. Targets10, 735–748 (2006).
   PubMed Web of Science ®Google Scholar
• Charakida A, Dadzie O, Teixeira F, Charakida M, Evangelou G, Chu AC. Calcipotriol/βmethasone dipropionate for the treatment of psoriasis. Expert Opin. Pharmacother.7, 597–606 (2006).
   PubMed Web of Science ®Google Scholar
• Ma Y, Khalifa B, Yee YK et al. Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. J. Clin. Invest.116, 892–904 (2006).
   PubMed Web of Science ®Google Scholar
• Peleg S, Ismail A, Uskokovic MR, Avnur Z. Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26–9228, a noncalcemic analog of vitamin D3. J. Cell. Biochem.88, 267–273 (2003).
   PubMedGoogle Scholar
• Peleg S, Uskokovic M, Ahene A, Vickery B, Avnur Z. Cellular and molecular events associated with the bone-protecting activity of the noncalcemic vitamin D analog Ro-26–9228 in osteopenic rats. Endocrinology143, 1625–1636 (2002).
   PubMedGoogle Scholar
• Adorini L, Penna G, Amuchastegui S et al. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J. Steroid Biochem. Mol. Biol.103, 689–693 (2007).
   PubMed Web of Science ®Google Scholar
• Harant H, Andrew PJ, Reddy GS, Foglar E, Lindley IJ. 1α,25-dihydroxyvitamin D3 and a variety of its natural metabolites transcriptionally repress nuclear-factor-κB-mediated interleukin-8 gene expression. Eur. J. Biochem.250, 63–71 (1997).
   PubMedGoogle Scholar
• Mora JR, Iwata M, Eksteen B et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science314, 1157–1160 (2006).
   PubMed Web of Science ®Google Scholar
• Mebius RE. Vitamins in control of lymphocyte migration. Nat. Immunol.8, 229–230 (2007).
   PubMed Web of Science ®Google Scholar
• Carlberg C, Dunlop TW. An integrated biological approach to nuclear receptor signaling in physiological control and disease. Crit. Rev. Eukaryot. Gene Expr.16, 1–22 (2006).
   PubMedGoogle Scholar
• Xystrakis E, Kusumakar S, Boswell S et al. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J. Clin. Invest.116, 146–155 (2006).
   PubMed Web of Science ®Google Scholar
• Grimes DS. Are statins analogues of vitamin D? Lancet368, 83–86 (2006).
   PubMed Web of Science ®Google Scholar
• Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol.6, 358–370 (2006).
   PubMed Web of Science ®Google Scholar
• Vollmer T, Key L, Durkalski V et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet363, 1607–1608 (2004).
   PubMed Web of Science ®Google Scholar
• Levin A, Li YC. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int.68, 1973–1981 (2005).
   PubMed Web of Science ®Google Scholar